

FOR IMMEDIATE RELEASE

CONTACT:
Kelly Sladek
SCORR Marketing
308.237.5567
Kelly@scorrmarketing.com

KCAS Expands Large Molecule Capabilities

(Shawnee, Kansas; September 9, 2010) – KCAS, LLC, a bioanalytical laboratory specializing in high-quality research and analytical services for pharmaceutical, biotech, animal health and medical device companies, is pleased to announce the expansion of its large molecule analysis capabilities.

KCAS welcomes Proveen Dass, Ph.D., a former graduate of the American University in Washington, D.C, who joins Masood Khan, Ph.D., senior director of immunoanalytical science and technology, and his ligand binding assay (LBA) team. As Associate Director, Dr. Dass will put to use his industry experience and assist Dr. Khan with the development of GLP-compliant and non-GLP assays for the conduct of large molecule bioanalytical studies, including PK/TK analysis, immunogenicity evaluation and biomarker quantification.

KCAS uses state-of-the-art immunoanalytical technologies to support large molecule bioanalysis for preclinical and clinical studies (Phase I - IV), as well as rapid bioanalysis for biomarker screening pilot projects.

"We are very fortunate to have both Dr. Khan and Dr. Dass at KCAS," stated President and Scientific Director of KCAS, Dari Dadgar, Ph.D. "Their combined knowledge and skill in working with large molecules, specifically LBA services, has positively impacted our capabilities and we look forward to propelled growth and expansion in the future."

In addition to the highly noted and qualified large molecule experts, Dr. Khan and Dr. Dass joining KCAS, the company has recently purchased Meso Scale Discovery's Sector Imager 6000, an electrochemiluminescence (ECL) detection platform. This high-tech equipment will enable KCAS to offer immunogenicity assays with better drug tolerance and multi-plex panels for biomarker assays.

About KCAS, LLC

KCAS provides a full range of high quality analytical services, specializing in bioanalytical research by "Advancing Science Through Curiosity™," to pharmaceutical companies of all sizes. For more than 30 years, KCAS has completed over 800 bioanalytical assays and thousands of PK, TK and BE studies. KCAS produces reliable and high-quality results for small molecule, large molecule and biomarker analysis. For more information about KCAS, visit www.kcasbio.com.

###